BUSINESS FOR THE FIRST NINE MONTHS OF 2024_____ Net sales: €155.4m (+6.8%) Gross margin: €121.7m (+3.5%)Continued growth for the digital marketing business with its gross margin up +14.1% Paris, 29 ...
"Biofrontera AG (ISIN: DE000A4BGGM7), an international biopharmaceutical company, today announced its financial results for the first nine months ended September 30, 2024. Key Financial Figures and ...